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Abstract:
Non-alcoholic fatty liver disease (NAFLD) results from an unequal uptake/storage and
export/oxidation of lipids within the liver and is often a secondary disease to type II diabetes
(22). NAFLD causes this imbalance of lipids by altering glucose and lipid metabolism, which
corresponds to a decrease in mitochondrial function leading to failure of the liver. One
established treatment for type II diabetes and NAFLD is the drug metformin, which has similar
properties to the newly discovered CTRP 3 protein which is part of a group of bioactive
molecules secreted by adipose tissue, collectively termed adipokines (2-4). Both have similar
effects on hepatic glucose and lipid metabolism and both specifically suppress hepatic
gluconeogenesis (11, 17, 27, 29). The revolutionary Seahorse extracellular flux analyzer was
used to measure the metabolism of H4IIE hepatocytes without use of radiolabeling (1). By
detecting the Oxygen Consumption Rate (OCR) of hepatocytes the level of metabolic function
within mitochondria can be measured. Once an effective protocol was established using this
new technology, hepatocytes treated with metformin had a significantly lower OCR compared
to control treated hepatocytes treated. However, H4IIE hepatocytes treated with metformin
and palmitate had a significant increase in OCR and eventually equilibrated with the lower OCR
of hepatocytes solely treated with metformin. With similar effect, hepatocytes treated with
CTRP3 and palmitate caused a drastic increase in OCR while hepatocytes treated with only
CTRP3 had a decrease in OCR. This suggests that CTRP3 increases fatty acid oxidation which
decreases lipid concentrations within hepatocytes which could mean future protection of liver
against NAFLD. In conclusion, our Seahorse XF analyzer models compare metformin and
CTRP3’s similarities and suggest the possible liver protective functions of CTRP3. Our results
will aid in future research of CTRP3 to further determine its possible uses as a treatment for
liver-associated diseases.

Introduction
The emergence of the Seahorse extracellular flux analyzer has uprooted the traditional
methods of measuring the metabolic activity of cells. The use of this machine allows one to
measure oxygen consumption rate, extracellular acidification rate and pH without the use of
radiolabeling molecules. One published paper has demonstrated the accuracy of measuring
mitochondrial function by specifically measuring fatty acid oxidation using the extracellular flux
analyzer compared to traditional radiolabeling of the fatty acid oxidation end product, 3HOH
(1).
The ability to make measurements of metabolic functions in a wide variety of cells within
minutes opens the door to a multitude of research opportunities. One such opportunity is
using H4IIE hepatocytes to study the effects of the newly discovered protein, C1q TNF Related
Protein 3 (CTRP3), on liver function. The CTRP3 protein is one of 15 CTRP proteins that are part
of a group of bioactive molecules secreted by adipose tissue, collectively termed adipokines (24). Adipokines play important roles in regulating insulin sensitivity and energy balance, but are
noticed to have unusually low and high circulating concentrations in medical cases of diabetes
or obesity (4).
The most heavily studied adipokine, adipocyte complement-related protein 30 kDa
(Acrp30/adiponectin), has a distribution of receptors throughout the peripheral systems which
allows Acrp30/adiponectin the ability to influence a variety of metabolic functions, such as;
insulin sensitizing, anti-inflammatory and anti-atherogenic properties (2, 4-10). The C1q/TNRrelated protein (CTRP) protein family was discovered by through a bioinformatics analysis of the

human genome based on a structural similarity to Acrp30/adiponectin (3). To date, 15 CTRP
family members have been identified, termed CTRP1-CTRP15. CTRP15 is also known as
myonectin as it is the only identified member of this protein family to be selectively expressed
from skeletal muscle instead of adipose tissue (ref Seldin 2013). Many CTRP proteins have
demonstrated unique and tissue specific metabolic functions (3, 11-16).
Out of the family of CTRP, CTRP3 is the one that we have focused on looking more in depth to
see its effect metabolic functions. Studies have already proven that CTRP3 has protective
qualities within the heart following an ischemia (19-20). In other studies it was found that
intraperitoneal injections of CTPR3 caused an acute decrease in blood glucose primarily by
reducing hepatic gluconeogenesis (11, 17). CTRP3 also reduces triglyceride accumulation within
the liver, but the exact mechanism is still not fully understood (27).
There is great potential for CTRP3 to become a therapeutic drug for liver associated diseases
due to how it affects hepatic lipid and glucose metabolism. A prominent liver disease is Nonalcoholic fatty liver disease (NAFLD) that results from an unequal uptake/storage and
export/oxidation of lipids within the liver (22). NAFLD causes this imbalance of lipids by
increasing glucose and lipid metabolism, which corresponds to a decrease in mitochondrial
function. The relationship between liver metabolism function and CTRP3 has not been fully
evaluated, but since CTRP3 can drastically reduce hepatic triglyceride accumulation it is likely
there are other metabolic processes within hepatocytes that are affected (23, 24, 25).
Patients with NAFLD have been shown to have significantly increased levels of hepatic
apoptosis due to continually high concentration of lipids, which leads to an increased severity

of the disease (25, 26). Proteins that function to counteract apoptosis, Bcl-xl and Mcl-1, are
shown to be reduced and make hepatocytes more vulnerable to oxidative stress and other
acute apoptotic stimulus within NAFLD patients (25). An effective anti-apoptotic therapy might
help to lessen the severity of this syndrome of NAFLD patients (26). Further hepatic research
has shown that CTRP3 prevents liver lipid accumulation by regulating triglyceride metabolism,
which may suggest CTRP3 directly or indirectly prevents hepatic lipoapoptosis (27). This, along
with the fact that CTRP3 has been shown to shield cardiac tissue from myocardiac infarction
induced apoptotic signaling, may indicate CTRP3 as a future protective therapeutic drug for
lipoapoptosis of NAFLD patients (20).
This is why it is with great importance that a model protocol be developed with H4IIE
hepatocytes using the Seahorse Extracellular Flux Analyzer so that hepatic metabolic effects of
CTRP3 can be measured. Since the technology of the extracellular flux analyzer is relatively
new, there is little information regarding its use related to H4IIE hepatocyte metabolism.
However, two papers have been our main focus to try to replicate and create a model for our
specific needs of measuring CTRP3 effects on H4IIE cells. The first paper proposed a protocol to
measure fatty acid oxidation within myoblasts using the analyzer (1). The second paper showed
a protocol for measuring the effects of the drug metformin on metabolic performance of H4IIE
hepatocytes (28).
By combining the protocols of both papers we could develop a well-defined study looking at the
effects of metabolism in metformin treated H4IIE hepatocytes. This would help to fine tune a
metabolism protocol with the seahorse XF analyzer in which metformin treatment would be

eventually replaced with CTRP3 treatment. Metformin is a great starting point because both
metformin and CTRP3 have very similar effects on hepatic glucose metabolism in that they both
suppress hepatic gluconeogenesis (11, 17, 27, 29). Metformin is also a wide-spread therapy in
the treatment of type 2 diabetes and NAFLD, which directly correlates with the potential
therapeutic uses of CTRP3 (11,17,27,29,30). So, profiling the metabolic effects of both CTRP3
and metformin on H4IIE cells may help to show the similarities of function and help CTRP3 to be
a new NAFLD therapy.

Materials and Methods

General Methodology
Growth of H4IIE hepatocytes. H4IIE hepatocytes were grown and maintained in cell culture
plates with growth media containing 10% fetal-bovine serum in high glucose DMEM via
standard aseptic cell culture techniques. Each cell culture dish was given fresh 15 ml of the 10%
FBS growth media every 48 hours for the duration of the growth process.
Seahorse XF analyzer Setup. There are two packages that are used with every experiment for
the XF analyzer. One is the injection well and must be incubated overnight in a non-CO2
incubator with 500 μl of XF calibrant in each well. The other package was the cell plate for
culturing the H4IIE cells. Once the cells are ready for experimentation and the injection plate

has calibrated overnight, then the injection plate’s wells were loaded with the needed
chemicals. Using the Seahorse XF analyzer’s “assay wizard” an experimental protocol was set
up to do a 3 minute session of mixing, a 2 minute session of time delay, and a 3 minute session
of measuring. All three of those actions counted as one cycle and were repeated until the
desired time is reached for the injections from the injection plate. The Seahorse analyzer then
gave step by step directions of what was needed. The XF measurements are non-destructive so
the metabolic rate of the same cell population can be measured repeatedly over time without
interruption.
Palmitate/BSA preparation. Seahorse provided protocol for preparing correct Palmitate/BSA
complex. Two separate 1 L beakers were warmed with 200 ml of tap water in a hot water bath.
A separate 250 ml beaker with a stir bar was then warmed in a 37 C water bath. Then, 9 ml of
5M NaCl stock solution was added to 291 ml of dH20 to make 300 ml of 150 mM NaCl. Ultra
fatty acid free BSA was weighed out to a mass of 2.267 g. Then 100 ml of the prepared 150 mM
NaCl was transferred to the pre-warmed 250 ml glass beaker with stir bar, which was then
placed on a stir plate. The weighed BSA was added to the beaker on the stir plate slowly with
continuous stirring. One of the pre-warmed 1L beakers with tap water was placed on a heated
stir place. The BSA solution beaker was covered with parafilm and then placed in the 1 liter 37
C0 beaker/water bath. The BSA solution beaker was stirred until completely dissolved and then
filtered with a vacuum. The filtered BSA solution had 50 ml transferred to a pre-warmed 250
ml beaker, covered with parafilm, and placed within the 1 L beaker. The filtered BSA solution
that remained was diluted with 50 ml of 150 mM NaCl solution to make a 0.17 mM stock
solution that was aliquoted into 4 ml glass vial at -20 C (this was BSA vehicle control).

Sodium palmitate was weighed out to a mass of 30.6 mg and added to 44 ml of the 150 mM
NaCl solution in a 50 ml Erlenmeyer flask. The palmitate flask was placed within the 1 Liter 70
C0 water bath. Once solutions achieved correct temperature, 40 ml of palmitate solution was
transferred to the BSA solution and stirred 1 hr at 40 C0. The final volume of palmitate/BSA
solution was adjusted to a volume of 100 ml to achieve a final concentration of 150 mM NaCl to
give a 1 mM palmitate solution, pH 7.4. The solution was prepared into 4 ml aliquots in glass
vials and stored at -20 C.
CTRP3 protein purification. As previously and routinely performed in the Peterson lab,
recombinant full-length mouse CTRP3, containing a C-terminal FLAG tag epitope (DYKDDDDK),
was produced in mammalian cells (17). Briefly, pCDNA3.1 expression constructs encoding Cterminal FLAG-tagged mouse CTRP3, were used in transient transfections to generate
recombinant proteins. HEK 293 cells (Grip-TiteTMcells, Invitrogen) were cultured in DMEM
containing 10% (v/v) bovine calf serum supplemented with 100 µg/ml penicillin and 100 µg/ml
streptomycin. Transfections were performed in HEK 293 cells using lipofectamine (Invitrogen)
or calcium phosphate method. At 24 h post transfection, media were replaced with serum-free
Opti-MEM media (Invitrogen) supplemented with vitamin C (0.1 mg/ml). Supernatants were
collected three times, every 48 h, pooled and purified using an anti-FLAG affinity gel according
to the manufacturer's protocol (Sigma), and eluted with 150 µg/ml FLAG peptide (Sigma).
Purified proteins were dialysed against 20 mM Hepes buffer (pH 8.0) containing 135 mM NaCl
in a 10 kDa cut-off Slide-A-Lyzer dialysis cassette (17).

Specific Methodology
1).Developing effect of metformin on H4IIE hepatocyte metabolism model
Cells were split into Seahorse XF 24 well plates to obtain 70% confluence within each of the 20
used wells (A1, C3, 4B and 6D were designated as cell-less temperature controls by XF
analyzer). Cells were allowed a day to attach and then were washed with serum-free low
glucose DMEM and allowed overnight incubation with serum-free low glucose DMEM. The
injection well plate was also incubated overnight with XF analyzer calibrant overnight in a nonCO2 incubator. After the overnight incubation, A 15 ml falcon tube was filled with 10 ml KHB
buffer supplemented with 100 μl of carnitine (0.5M); labeled as “control.” Carnitine is an
amino acid that has been found to aid in liver lipid metabolism and protect mitochondrial
function (32). A 50 ml falcon tube was filled with 30 ml of KHB buffer supplemented with 300
μl carnitine (0.5 mM) and metformin (2mM); labeled as “experimental.”
The 24 well plate of cells were washed with 250 l of control. The first 3 columns were then
filled with 250 μl of control and the last 3 columns were filled with experimental. The cells
were then incubated for 1 hour. During the one hour incubation 1mM decoupler 2,4dinitrophenol (DNP) was diluted with KHB buffer and added to well A of every injection well
(final concentration 100 μM DNP). The protocol was set to inject well A of the mitochondrial
DNP, which is an anti-obesity drug at 104 minutes (31). This was followed by another 48
minutes worth of mix, time delay, and measure periods. Because we were only measuring one
variable there is an n=10 for each group. Our model paper (28) was followed exactly at first,
but slight variations were made with each experiment treatment to make a better model of

oxygen consumption rates of metformin treated H4IIE hepatocytes, which correlate with
mitochondrial/metabolic function.
2). Effect of metformin on H4IIE hepatocyte metabolism in presence of Palmitic acid model
The protocol for examining metformin was followed with adjustments discussed in results-2
section. Palmitic acid was also introduced into the protocol and was added as an injection
within the Seahorse XF analyzer, which gave n=5 for each experimental group. Palmitic acid or
the vehicle control BSA was added (final concentration 0.2 mM) to metformin treated
hepatocytes and vehicle control KHB. Palmitic acid was chosen because it is a saturated fatty
acid that is easily taken up and metabolized by the cell and will promote the expression of proinflammatory, cytokines, disrupts insulin signaling, and stimulates apoptosis. Excess lipid
accumulation leads to increased oxidative stress and mitochondrial dysfunction, which will be
noted by the analyzer (24). Palmitic acid treatment will allow us to measure the different rate
of palmitate utilization within cells treated with or without metformin, which could show
possible protective characteristic of metformin in H4IIE cells.
3). Effect of CTRP3 on H4IIE hepatocyte metabolism in presence of palmitate model
The previous protocol using metformin and palmitate treated cells was followed. However,
cells were treated with CTRP3 (5 μg/ml) or without CTRP3 in place of metformin. This gave us
n=5 for each treatment group of hepatocytes.

RESULTS
Results-1: Developing model to test the effect of metformin on H4IIE cells
Results-1a: Following the exact procedure described by Logie, et al (28).
A

C

B

D

Figure 1. H4IIE hepatocytes treated as described by Logie et al (28), where time 0 is 1 hour
incubation with metformin. Hepatocytes were treated with metformin (green) or vehicle control
(blue). The vertical line represents the injection of mitochondrial decoupler, DNP. A, Oxygen
Consumption Rate (OCR) presented in pMol/min. B, OCR presented as percent change compared
to basal. When OCR is increased/decreased over time it is shown a percent increase/decrease
according to basal OCR rate (100%). C, Shows the increasing pH levels of both group types. D,
Published paper by Logie et al (28) OCR graph stimulation without (squares) or with
metformin (inverted triangles). OCR, Oxygen Consumption Rate; Vehicle control, KHB.

The protocol within paper (28) was followed exactly and shown in figure 1D, but as can be seen
in figure 1B we had very different results. The cells continually decrease in oxygen
consumption rate (OCR) until the H4IIE hepatocytes reached 0% OCR as shown in figure A,
which indicates the cells were dying. The cells dying would explain why the decouple DNP did
not work after injection. Figure 1C shows that the pH of the cells increased as high as 8.6,
which is most likely the reason for the cell death and steadily decreasing OCR. This experiment
was repeated, but changing the overnight incubation by decreasing to 17 hours. However, the
results were exactly the same as shown in figure 1 and with the same pH change as noted in
figure 1C. Our results did not match the published work by Logie et al (28), therefore the next
series of experiments were performed.

Results-1b: First series of modifications
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Figure 2. H4IIE hepatocytes treated as described in published paper by Logie et al (28) with
adjustments described in results. Hepatocytes were treated with either metformin and DNP
(green), metformin and FCCP (pink), vehicle control and DNP (blue), or vehicle control and FCCP
(red). The vertical line with letter A represents the injection of metformin or vehicle control. The
vertical line with letter B represents the addition of either DNP mitochondrial decoupler or FCCP
mitochondrial decoupler. A, Oxygen Consumption Rate (OCR) presented in pMol/min. B, OCR
presented as percent change compared to basal. When OCR is increased/decreased over time it is
shown a percent increase/decrease according to basal OCR rate (100%). C, Shows the increasing
pH levels of both group types. D, Published paper by Logie et al (28) OCR graph in which we are
trying to model stimulation without (squares) or with metformin (inverted triangles)
(28). Vehicle control, KHB.

This attempt at making a better model changed many different variables from the original
protocol. There was no longer any overnight incubation of serum free DMEM or use of krebs
buffer within the H4IIE hepatocytes. Instead, cells were split into XF 24 well plate and allowed
over 4 hours to properly attach with 100 ul of normal cell media (10% FBS DMEM) within each
well. Well volume was brought to 250 an hour before experiment begins, after allowing at least
4 hours to attach. Metformin was not added to the media before experiment, but was instead
weighed out to a mass of 0.01 g and dissolved within 5 ml of KHB buffer. The metformin was
then made to be the first injection (final concentration in well 2mM) within the seahorse wells
after 24 minutes of basal cell metabolism readings. The second injection was then made to be
either DNP or FCCP to further investigate the possibility of a better performing mitochondrial
decoupler. The pH in figure 2C still showed an increase, but was found to be significantly lower
than the pH increase in figure 1C. Overall cell metabolism was significantly improved within
this protocol as shown within figure 2A and 2B. Metformin treated H4IIE hepatocytes caused a
decrease in OCR when compared to vehicle control KHB, which mimics the effects shown within
our model pape shown in figure 2D (28). FCCP also showed to be a slightly better mitochondrial
decoupler when compared to DNP. This was established as our protocol for measuring the
effect of metformin on H4IIE hepatocyte metabolism, except FCCP was decided to be the
designated mitochondrial decoupler injected. Our results did not match the published work by
Logie et al (28), therefore the next series of experiments were performed.

Results-2: Developing model to test effect of metformin in presence of Palmitic acid
Results-2a:

A

B

Figure 3. H4IIE hepatocytes were treated with metformin and palmitate (green), metformin and
BSA (pink), KHB and palmitate (blue), or KHB and BSA (red). Vertical line letter A is injection either
metformin or vehicle control, vertical line B is either Palmitate or vehicle control injection, vertical
line letter C is injection of FCCP A, Oxygen Consumption Rate (OCR) presented in pMol/min. B,
Represents figure 3A’s data as OCR percent where baseline rate data is set at 100%. Metformin
vehicle control, KHB; Palmitate vehicle control, BSA

The experimnts described for figure 2 were duplicated, except (100uM) FCCP was the only
mitochondrial decoupler. Further, the addition of the free fatty acid palmitate was also
included. Thus, well A injected every cell with either metformin or vehicle control (KHB) and
well B injected every cell with either palmitate or the palmitate vehicle control (BSA). This
model shows how the hepatocytes first react to the injection of metformin followed by how
they react over the next 130 minutes. Metformin treated H4IIE cells differentiated themselves
from the metformin vehicle control hepatocytes by having significantly lower OCR% rates.

Results-2b

A.

B.

C.

D.
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F

Figure 4. Time zero represents 1 hour incubation with either metformin or metformin vehicle
control. Injection well A represents the injection of either palmitate or palmitate vehicle control.
Injection well B represents the injection of mitochondrial decoupler FCCP to all cells. A, Oxygen
Consumption Rate (OCR) presented in pMol/min. Rest of graphs present OCR% where baseline rate
data is set at 100%. B, OCR% all experimental groups. C, H4IIE hepatocytes treated with metformin
vehicle control and palmitate (blue) or metformin vehicle control and palmitate vehicle control
(red). D, H4IIE hepatocytes treated with metformin and palmitate vehicle control (pink group) or
metformin vehicle control and palmitate vehicle control (red). E, H4IIE hepatocytes treated with
metformin and palmitate (green) or metformin and palmitate vehicle control (pink). F, H4IIE
hepatocytes treated with metformin and palmitate (green) or metformin vehicle control and
palmitate (blue). Metformin vehicle control, 10% FBS DMEM; Palmitate vehicle control, BSA

The protocol followed is described in results 2a except that cells were incubated with 2mM
metformin one hour prior to beginning seahorse XF analyzer. So, the only injections in the
Seahorse XF analyzer were palmitate or BSA vehicle control and FCCP mitochondrial decoupler.
Logie et al (28), reported that it took one hour exposure to metformin in order to show its
effects. So we concentrated on what happens to hepatocyte metabolism specifically after that
hour incubation with metformin and in the presence of palmitate. Metformin without
palmitate had a lower OCR% when compared to all the other groups. However, metformin and
palmitate had a sharp OCR% increase right after palmitate injection and eventually equilibrated
with the lower OCR% of solely metformin treated hepatocytes. Hepatocytes treated with the
metformin vehicle control (10% FBS DMEM) and palmitate had a lower OCR % than the double
control hepatocytes.

Results-3: Developing model to test the effect of CTRP3 with palmitate on H4IIE cells

A.

B.

C.

D.

Figure 5. Time zero represents one hour incubation of H4IIE hepatocytes with or without CTRP3.
Vertical line with letter a represents injection of palmitate or palmitate vehicle control, and letter b
represents injection of FCCP. A, OCR measured in pmol/min of CTRP3 treated (pink) and no CTRP3
(red) without presence of palmitate. B, OCR% baseline measure of figure 5A data. C, OCR measured
in pmol/min of CTRP3 with palmitate (green) or no CTRP3 with palmitate (blue). D, OCR% baseline
measure of figure 5C data.

Figures 5A and 5B show that there is no difference between hepatocytes without palmitate
treatment, even when hepatocytes were treated with CTRP3. However, palmitate treated cells
had significantly different responses depending on whether or not hepatocytes were treated
with CTRP3. H4IIE hepatocytes that were treated with CTRP3 and palmitate had a drastic
increase in OCR due to increased fatty acid oxidation. However, cells that were treated with
CTRP3 without palmitate treatment had a drastic decrease in OCR, due to decrease in
mitochondrial metabolic activity. Interestingly, mitochondrial decoupler FCCP caused a sharp
OCR decrease only with CTRP3 and palmitate treated hepatocytes but can’t be explained
currently. Due to the complexity of extracting CTRP3 and diminished stock supply this was the
only experimental run performed.

DISCUSSION

We were unable to replicate the data presented by Logie et al, (28) published protocol for
measuring metabolic activity of H4IIE hepatocytes using the seahorse XF analyzer. The cells all
appeared to die as noted by the extremely low oxygen consumption rate (OCR) that eventually
gets down to 0. One theory is that since the seahorse XF analyzer does not regulate CO2 levels
the cell media would have continually dropping levels of acidic CO2 solution, creating a basic
solution. In figure 1C it is shown that the pH got as high as 8.6 which is too basic for cells to
survive. The lightly buffered KHB solution that the cells were kept in during the use of the
Seahorse XF analyzer thus did not properly keeping the solution at a neutral pH. It was also
thought that incubating the cells overnight in serum free cell media may have starved the cells
to the point of death. Since all of the cells were unhealthy and dying the effects of metformin
could not be properly measured and changes were needed for the protocol used.
Adjustments were made to eliminate the overnight incubation with serum free cell media and
discontinue the use of KHB. It was found that by allowing 4 hours for the H4IIE hepatocytes to
properly attach after splitting cells into Seahorse XF 24 well plate and keeping the cells within
10% FBS cell media, even when running within Seahorse XF analyzer, created a healthier
environment for the cells. Figure 2C shows that the pH levels with the adjusted protocol rose
to a maximum of an 8.2 pH, which is significantly lower than the 8.6 pH shown in figure 1C.
Figure 2A also shows that OCR started out at approximately 300 which was significantly higher

than the OCR of 30 shown in figure 1A. This indicates that the cells were in a healthier
environment, which allowed them to survive and present a model of the effects of metformin.
We now have similar data and figures when comparing the OCR % graph in figure 2B to
published OCR% graph Logie et al in figure 2D (28). By analyzing figures 2A and 2B, H4IIE
hepatocytes treated with metformin are shown to have significantly lower oxygen consumption
rates. Metabolic respiration is an aerobic process that requires oxygen as the final electron
acceptor. So, hepatocytes that have a lower rate of oxygen consumption directly translate to a
lower rate of metabolic respiration. These results are supported by research suggesting that
metformin (similar to CTRP3) alters hepatic glucose metabolism by reducing hepatic
gluconeogenesis (11, 17, 27, 28, 29). The exact mechanism of how metformin reduces
gluconeogenesis is still heavily debated. However, it is currently suggested that metformin
reduces mitochondrial respiration by inhibiting complex I and by decreasing hepatic energy
state, which is directly expressed in our data figures 2A and 2B by the lower OCR (27, 33,34).
Two models were created in studying the effects of hepatocytes treated with metformin and
palmitate. Figure 3 shows the effects of metformin the instant it was injected. Figure 4
specifically demonstrates on the effects of metformin after 1 hour long incubation. Both
figures show that metformin treated H4IIE hepatocytes have consistently lower OCR. However,
hepatocytes treated with metformin and palmitate show a significant increase in OCR after
palmitate injection compared to the lower OCR of hepatocytes without palmitate. This can be
explained by the fact that metformin reduces mitochondrial respiration by inhibiting complex I,
which in return increases the activation of AMP-activated protein kinase (27, 33, 35). An

increase in AMP-activated protein kinase increases the rate of fatty acid metabolism and
mitochondrial biogenesis, which would require the hepatocytes to consume more oxygen (36,
37). This elevation of OCR following palmitate injection is then most likely due to the elevated
utilization of palmitate through fatty acid oxidation by metformin treated H4IIE hepatocytes. It
appears that palmitate was then continually depleted, thus reducing fatty acid oxidation, and
explains the following decline in OCR until equilibrating with the lower OCR of hepatocytes
solely treated with metformin.
Although only one experimental group measuring CTRP3’s metabolic effect on H4IIE
hepatocytes was performed, there was very interesting results. Both hepatocyte groups
without the injection of palmitate behaved exactly the same, showing CTRP3 did not have an
effect in this case. However, CTRP3 with palmitate drastically increased OCR while hepatocytes
that were only treated with palmitate drastically decreased OCR. Even though the exact
mechanism is still not known, this models the fact that CTRP3 reduces triglyceride accumulation
within the liver (27). The sudden increase after palmitate injection suggests that CTRP3
drastically increased fatty acid oxidation in order to utilize the abundance of fatty acid
palmitate. This closely mimics the effects of metformin with palmitate on H4IIE hepatocytes, as
shown in figure 4, and gives a great starting point for further research on liver-protective
characteristics of CTRP3. In conclusion, Our Seahorse XF analyzer data allows the comparison
of metformin and CTRP3’s similarities and suggest the possible liver protective functions of
CTRP3. Our results will aid in future research of CTRP3 to further determine its possible uses as
a treatment for liver-associated diseases.
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